- Policy
- Doctors consider 'efficacy' over cost on anticancer Rx
- by Lee, Hye-Kyung Nov 15, 2019 06:29am
- Domestic oncologists have considered more efficacy and safety than the medicne expense when they prescribe anticancer drugs It implies that health authorities need to mix the ratio of anticancer efficacy and toxicity when applying the valuation tools of the European Society for Medical Oncology(ESMO) and the American Society of Clinical Oncolo
- Product
- 7 out of 10 doctors exposed to patient violence
- by Kang, Shin-Kook Nov 15, 2019 06:29am
- Apparently, seven out of ten doctors have faced verbal abuse or physical violence against them by a patient or their family. On Nov. 13, Korean Medical Association (KMA, President Choi Dae-zip) published a result of an urgent survey conducted on 2,034 member doctors of the organization. The survey result found among 1,455 doctors (71.5 p
- Policy
- 4200 items subject to ATP-based price reduction by 1%
- by Lee, Hye-Kyung Nov 15, 2019 06:28am
- Korean regulators have decided to reduce drug prices of about 4,200 items based on actual transaction price (ATP) from Jan. 1 next year. Until Nov. 11, Health Insurance Review and Assessment Service (HIRA) informed details of price reduction to pharmaceutical companies with already-listed drugs subject to the reduction, and allowed them to
- Company
- XOSPATA , AML Medicine landing soon in Korea
- by Eo, Yun-Ho Nov 15, 2019 06:28am
- It is anticipated that new AML (acute myeloid leukemia) drugs which are lack of the treatment will be approved . According to the related industry on the 15th, Astellas Pharmaceuticals is in the process of approving from MFDS for 'Acute myeloid leukemia (AML) drug named Xospata (Gilteritinib). The drug is already approved in 2018
- Policy
- Pharmaceutical spending structure needs to be reorganized
- by Lee, Jeong-Hwan Nov 14, 2019 05:40pm
- We need to increase the expenditure of new drugs in drug costs far more than now. Patent expiration drugs must be left out of the market and replaced by generics for health insurance to be kept. However, since the structure could not be broken, the reform of the generic drug price system, which is a transitional measure, has started. It is
- InterView
- I know CRA grievances better than anyone else
- by Lee, Tak-Sun Nov 14, 2019 09:59am
- For CRA(Clinical Research Associate), it is very hard to communicate with many professional people. It's even harder if you don't have expertise. I wish my juniors would work with proud. I would like to have the pride of being an expert that communicates effectively with clinical expertise, monitors clinical practice, and leads clinical pra
- Policy
- Zejula max reimbursed price 76,400 won from Dec. 1
- by Kim, Jung-Ju Nov 14, 2019 09:08am
- From December, Takeda Pharmaceutical Korea’s ovarian cancer treatment, Zejula 100mg capsule (niraparib) would be on the insured drug list at a price of 76,400 won. Although it is more cost-effective than the alternative option Lynparza, Zejula received the same price cap because Lynparza was listed via pharmaceoeonomics (PE)-exempted risk shari
- Policy
- 62 DI including Belviq® and CONTRAVE®,added to DUR
- by Lee, Tak-Sun Nov 14, 2019 09:07am
- The MFDA(Ministry of Food and Drug Safety) has announced additional contraindicated DI(Drug Interaction) medicines that will be updated in the DUR (Drug Utilization Review). Especially, one of the antiobesity medicines, Contrave®(Bupropion-Naltrexone) is contraindicated with Belviq® (Locaserine HCl), and , Cough®, one of expectorants w
- Company
- Samsung Bioepis CEO notes 3 reasons why CAR-T struggles
- by Kim, Jin-Gu Nov 14, 2019 09:07am
- Ko Hang-Seung, CEO of Samsung Bioepis Co., picked three reasons CAR-T cell therapy (“CAR-T”) is struggling &8211; price, patient size and productivity. On Nov. 12, CEO Ko shared his opinions about CAR-T and other next generation treatment options during his keynote speech at BIOplus 2019 in COEX, Seoul. “Data was fairly good when
- Company
- Merck Korea vs GM employee feud sees no end
- by An, Kyung-Jin Nov 14, 2019 09:07am
- After licensing out antihypertensive and anti-diabetic treatments, Merck Korea is finally, and completely, shutting down its General Medicine (GM) division. However, an intense conflict with labor union has deepened as more than a half of the employees have not reached an agreement with the company’s management. The company offering e
